Literature DB >> 9746617

Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice.

C M Bosio1, I M Orme.   

Abstract

Vaccination of mice with Mycobacterium bovis culture filtrate proteins (CFP), prepared in a variety of adjuvants (aluminum hydroxide, Quil-A, and dimethyldioctyldecyl ammonium bromide [DDA]), provided significant protection against an aerosol challenge of virulent M. bovis. Additionally, vaccination with CFP in DDA or Quil-A did not sensitize mice to M. bovis purified protein derivative.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9746617      PMCID： PMC108628     

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  25 in total

Review 1.  Protein antigens of mycobacteria studied by quantitative immunologic techniques.

Authors:  M Harboe; H G Wiker; S Nagai
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

2.  Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.

Authors:  S L Baldwin; C D'Souza; A D Roberts; B P Kelly; A A Frank; M A Lui; J B Ulmer; K Huygen; D M McMurray; I M Orme
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones.

Authors:  S Hussein; J Curtis; H Akuffo; J L Turk
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

4.  Aerogenic vaccination of mice with Mycobacterium bovis BCG.

Authors:  I M Orme; F M Collins
Journal:  Tubercle       Date:  1986-06

5.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation.

Authors:  J W Mannhalter; H O Neychev; G J Zlabinger; R Ahmad; M M Eibl
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

6.  Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG.

Authors:  R L Anacker; W R Barclay; W Brehmer; C L Larson; E Ribi
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

7.  Biological activity in sensitized guinea pigs of MPB 70, a protein specific for some strains of Mycobacterium bovis BCG.

Authors:  K Hasløv; A B Andersen; M W Bentzon
Journal:  Scand J Immunol       Date:  1987-10       Impact factor: 3.487

8.  Purification and characterization of major antigens from a Mycobacterium bovis culture filtrate.

Authors:  T Fifis; C Costopoulos; A J Radford; A Bacic; P R Wood
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Immunization of mice with mycobacterial culture filtrate proteins.

Authors:  R D Hubbard; C M Flory; F M Collins
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

10.  Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines.

Authors:  I M Orme
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441
View more
  9 in total

1.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis.

Authors:  D N Wedlock; B Vesosky; M A Skinner; G W de Lisle; I M Orme; B M Buddle
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.

Authors:  D Neil Wedlock; Michel Denis; Margot A Skinner; Jessica Koach; Geoffrey W de Lisle; H Martin Vordermeier; R Glyn Hewinson; Sylvia van Drunen Littel-van den Hurk; Lorne A Babiuk; Rolf Hecker; Bryce M Buddle
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions.

Authors:  Nasreena Bashir; Fozia Kounsar; Sangita Mukhopadhyay; Seyed E Hasnain
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

5.  A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis.

Authors:  M A Skinner; A J Ramsay; G S Buchan; D L Keen; C Ranasinghe; L Slobbe; D M Collins; G W de Lisle; B M Buddle
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 6.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

7.  A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis.

Authors:  Margot A Skinner; Bryce M Buddle; D Neil Wedlock; Denise Keen; Geoffrey W de Lisle; Ricardo E Tascon; Jose Candido Ferraz; Douglas B Lowrie; Paul J Cockle; H Martin Vordermeier; R Glyn Hewinson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages.

Authors:  Pramod K Giri; Nicole A Kruh; Karen M Dobos; Jeff S Schorey
Journal:  Proteomics       Date:  2010-09       Impact factor: 3.984

9.  TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals.

Authors:  Owais Mohammad; Jagdeep Kaur; Gurpreet Singh; Syed Mohd Faisal; Asim Azhar; Mohd Ahmar Rauf; Umesh Dutt Gupta; Pushpa Gupta; Rahul Pal; Swaleha Zubair
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.